Last reviewed · How we verify
ACT-539313
ACT-539313 is a selective dopamine D2 receptor antagonist.
ACT-539313 is a selective dopamine D2 receptor antagonist. Used for Treatment-resistant schizophrenia.
At a glance
| Generic name | ACT-539313 |
|---|---|
| Sponsor | Idorsia Pharmaceuticals Ltd. |
| Drug class | Dopamine D2 receptor antagonist |
| Target | D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 2 |
Mechanism of action
ACT-539313 works by blocking the action of dopamine at the D2 receptor, which is involved in various physiological processes including movement and mood regulation. This blockade is thought to contribute to its therapeutic effects.
Approved indications
- Treatment-resistant schizophrenia
Common side effects
- Nausea
- Headache
- Dizziness
- Somnolence
Key clinical trials
- Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder (PHASE2)
- A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACT-539313 CI brief — competitive landscape report
- ACT-539313 updates RSS · CI watch RSS
- Idorsia Pharmaceuticals Ltd. portfolio CI